Novonesis_Logo (1).png
Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration
May 03, 2024 01:57 ET | Novozymes A/S
For the first quarter as Novonesis, the company delivers 4% organic sales growth in line with expectations. Novonesis maintains the 2024 outlook of 5-7% organic sales growth with an adjusted EBITDA...
Novonesis_Logo (1).png
Trading statement Q1 2024
May 03, 2024 01:56 ET | Novozymes A/S
Novonesis realized 4% organic sales growth in line with expectations and maintains 2024 outlook. Ester Baiget, President & CEO: “I am pleased with the first quarter organic sales growth of 4%...
Novonesis_Logo (1).png
Resolutions from the annual shareholders’ meeting 2024
April 30, 2024 12:02 ET | Novozymes A/S
Today an ordinary shareholders’ meeting was conducted. The following resolutions were made:•  Approval of the audited Annual Report for 2023•  Approval of distribution of profit with payment of an...
Novonesis_Logo (1).png
Invitation to the annual shareholders’ meeting
April 08, 2024 09:17 ET | Novozymes A/S
The annual shareholders’ meeting will be held on Tuesday April 30, 2024 at 4:00 pm CET at Bella Center, Center Boulevard 5, Denmark. The distribution of profit will be addressed at the meeting and...
Novonesis_Logo (1).png
Share-based legacy RSU program granted
April 08, 2024 05:58 ET | Novozymes A/S
Share-based legacy RSU program granted Novonesis’ Board of Directors has following the merger with Chr. Hansen Holding A/S (“Chr. Hansen”) today approved the continuation in 2024 of a...
Novonesis_Logo
2024 outlook and pro forma financials
March 21, 2024 02:26 ET | Novozymes A/S
Novonesis provides outlook for 2024 with expected 5-7% organic sales growth and ~35% adj. EBITDA margin. Pro forma financials disclosed. Ester Baiget, CEO of Novonesis, said: “Today we provide...
Novonesis_Logo
Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21
March 18, 2024 10:26 ET | Novozymes A/S
Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21 at 9.00am CET. To join the live webcast, please click here. To register and receive access...
Resolutions from the Extraordinary Shareholders’ Meeting 2024
March 04, 2024 11:06 ET | Novozymes A/S
Company Announcement no. 10 March 4, 2024Today an extraordinary shareholders’ meeting was conducted. The following resolutions were made: Adoption of Novonesis A/S as secondary name and...
logo.jpg
Invitation to an extraordinary shareholders’ meeting of Novozymes A/S
February 09, 2024 04:00 ET | Novozymes A/S
An extraordinary shareholders’ meeting of Novozymes A/S will be held on Monday March 4, 2024 at 4:00 pm CET at Boege Alle 10-12, 2970 Hoersholm, Denmark. Attachments ...
logo.jpg
The Novozymes Report 2023
February 08, 2024 13:52 ET | Novozymes A/S
This annual report has been released subsequent to the approval of the combination of Novozymes and Chr. Hansen on January 29, 2024. The new combined group is called Novonesis. As an annual...